Determination of galactose elimination capacity after intravenous administration in patients with chronic liver diseases. 1993

V Kupcová, and L Turecký, and E Brixová
II. interná klinika LFUK v Bratislave, Slovakia.

The authors describe a simple method of examination of galactose elimination capacity after intravenous administration of a twenty per cent solution in the total dose of 0.5 g galactose/kg body weight. After enzymatic determination of galactose concentration in six samples of venous blood (taken within 25, 30, 35, 40, 45 and 50 minutes after finishing the galactose infusion) the elimination curve of galactose and the intersection point with the time axis (t) is assessed and the galactose elimination capacity is calculated. In patients with liver steatosis and steatofibrosis, chronic hepatitis and liver cirrhosis the mean values of galactose elimination capacity were significantly lower in comparison with healthy volunteers. The method is sufficiently reliable, precise and quickly performable. It is suitable for evaluation and monitoring of the functional liver capacity, severity and progression rate of liver diseases. (Tab. 1. Fig. 2. Ref. 28).

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008107 Liver Diseases Pathological processes of the LIVER. Liver Dysfunction,Disease, Liver,Diseases, Liver,Dysfunction, Liver,Dysfunctions, Liver,Liver Disease,Liver Dysfunctions
D008111 Liver Function Tests Blood tests that are used to evaluate how well a patient's liver is working and also to help diagnose liver conditions. Function Test, Liver,Function Tests, Liver,Liver Function Test,Test, Liver Function,Tests, Liver Function
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D005690 Galactose An aldohexose that occurs naturally in the D-form in lactose, cerebrosides, gangliosides, and mucoproteins. Deficiency of galactosyl-1-phosphate uridyltransferase (GALACTOSE-1-PHOSPHATE URIDYL-TRANSFERASE DEFICIENCY DISEASE) causes an error in galactose metabolism called GALACTOSEMIA, resulting in elevations of galactose in the blood. D-Galactose,Galactopyranose,Galactopyranoside,D Galactose
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

V Kupcová, and L Turecký, and E Brixová
November 1993, Scandinavian journal of clinical and laboratory investigation,
V Kupcová, and L Turecký, and E Brixová
February 2011, Scandinavian journal of gastroenterology,
V Kupcová, and L Turecký, and E Brixová
January 1988, Hepatology (Baltimore, Md.),
V Kupcová, and L Turecký, and E Brixová
March 1964, Acta medica Scandinavica,
V Kupcová, and L Turecký, and E Brixová
June 1991, Schweizerische medizinische Wochenschrift,
V Kupcová, and L Turecký, and E Brixová
May 2022, Scandinavian journal of gastroenterology,
V Kupcová, and L Turecký, and E Brixová
November 1973, Surgery,
Copied contents to your clipboard!